How This Evidence Evolved
Gastric Cancer Lymphadenectomy
Defining the Optimal Extent of Lymph Node Dissection for Gastric Cancer
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
30-day morbidity: laparoscopic 16.6% vs open 24.1% (P=0.003); 90-day mortality 0.4% vs 0.6% (P=0.682)
Overall survival — neoadjuvant S-1/cisplatin did not improve survival vs D2 gastrectomy with adjuvant therapy
3-year relapse-free survival: laparoscopic 80.3% vs open 81.3% (HR 1.035, 95% CI 0.762-1.406; P for noninferiority=.039)
Integration into clinical practice guidelines and recommendations
D2 for potentially curable cT2–T4 or cT1N+; laparoscopic distal gastrectomy ≥Stage II strongly recommended with qualified supervision.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients
Operative mortality: D2 10% vs D1 4% (P=0.004); complications: 43% vs 25% (P<0.001)
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
15-year gastric cancer-related death — D2 lower locoregional recurrence and cancer-specific death vs D1
Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT)
30-day morbidity: laparoscopic 16.6% vs open 24.1% (P=0.003); 90-day mortality 0.4% vs 0.6% (P=0.682)
Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial
Overall survival — neoadjuvant S-1/cisplatin did not improve survival vs D2 gastrectomy with adjuvant therapy
Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial.
3-year relapse-free survival: laparoscopic 80.3% vs open 81.3% (HR 1.035, 95% CI 0.762-1.406; P for noninferiority=.039)
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.